期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗VEGFR-2嵌合Fab抗体对裸鼠肝癌原位移植瘤的治疗作用

Therapeutical effect of chimeric anti-VEGFR-2 Fab antibody on orthotopic xenograft of hepatocellular carcinoma in BALB/c nude mice
原文传递
导出
摘要 目的检测抗血管内皮生长因子受体2(VEGFR-2)嵌合Fab抗体对裸鼠肝癌原位移植瘤的治疗作用。方法 40只4周龄雄性BALB/c裸鼠建立肝癌H22细胞移植瘤模型后随机均分为Fab抗体(A)组和生理盐水对照(B)组。比较两组裸鼠生存时间、移植瘤病理变化及微血管密度(MVD)。结果成功建立裸鼠H22肝癌原位移植瘤模型,HE染色显示肝细胞肝癌。A组裸鼠中位数生存时间明显长于B组(20.0dvs.14.0d)(P<0.01);A组肝脏实体瘤内MVD较B组显著减少(8.65±1.79vs.25.64±1.53)(P<0.05)。结论抗VEGFR-2嵌合Fab抗体对裸鼠肝癌原位移植瘤有治疗作用。 Objective To investigate the therapeutical effect of chimeric anti-vascular endothelial growth factor receptor（VEGFR）-2 Fab antibody on orthotopie xenograft in BALB/c nude mice. Methods The orthotopic xenograft model of hepatocellular carcinoma H22 cells was established in 40 nude mice, which were equally randomized into two groups of A（treated with chimeric anti- VEGFR-2 Fab antibody） and B（treated with normal saline）. The survival time, pathological changes and microvessel density（MVD） in H22 xenografts were compared between two groups. Results An orthotopic xenograft model of hepatocellular carcinoma was successfully created in nude mice, which was confermed as hepatocellular carcinoma by hematoxylin-eosin staining. The mean survival time was longer in group A than that in group B（20. 0 d vs. 14. 0 d） （P〈0. 05）. MVD in the xenografts was less in group A than that in group B（8. 65±1.79 vs. 25.64±1.53）（P〈0. 05）. Conclusion The chimeric anti-VEGFR-2 Fab antibody has some therapeutical effect on an orthotopic xenografts in nude mice.
作者 李倩君 潘峰 王丙剑 朱进 张建民 吴亚夫 周传文
机构地区 南京医科大学附属淮安第一医院消化病科 南京军区军事医学研究所 南京医科大学鼓楼临床医学院肝胆外科
出处 《江苏医药》 CAS 北大核心 2013年第5期506-508,F0002,共4页 Jiangsu Medical Journal
基金 南京医科大学科技发展基金重点项目(2011NJMU241)
关键词 肝癌 血管内皮生长因子受体2 嵌合Fab抗体 Hepatocellular carcinoma Vascular endothelial growth factor receptor-2 Chimeric Fab antibody
分类号 R735 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Ivy SP, Wick JY, Kaufman BM. An overview of small- molecule inhibitors of VI：GFR signaling[J]. Nat Rev Clin Oncol, 2009,6(I0) : 569-579.
  • 2Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevaeizumab and VEGFR tyrosine kinase inhibitors[J]. Curr Treat Options Oncol, 2007,8 (1) : 15-27.
  • 3Vokes E, Herbst R, Sandier A. Angiogenesis inhibition in the treatment of lung cancer[J]. Clin Adv Hematol Oncol, 2006, 4(11 Supp1 23) : 1-10.
  • 4Bellon A,Luchino J,Haigh K,et aJ, VF_.GFR-2 (KDR/Flkl) signaling mediates axon growth in response to semaphorin 3E in the developing brain[J]. Neuron, 2010,66(2) : 205-219.
  • 5Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface[J]. Science, 1985,228(4705) : 1315-1317.
  • 6张建民,施晓雷,朱进,吴亚夫.抗VEGFR-2嵌合Fab抗体对鼠肝癌原位移植瘤及其新生血管的抑制作用[J].世界华人消化杂志,2010,18(34):3621-3626. 被引量：2
  • 7Zhong G, Zhang S, Li Y, et ak A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice[J]. Cancer Lett,2010,295(1) :124-133.
  • 8Zhu AX,Stuart K,Blaszkowsky LS, et a[. Phase 2 study Of cetuximab in patients with advanced hepatoceUular carcinoma [J]. Cancer,2007,110(3) :581-589.
  • 9Schirrmann T, Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display[J]. Methods Mol Biol, 2010,651 : 177-209.
  • 10Dobrucki LW, Meoli DF, Hu J, et al. Regional hypoxia correlates with the uptake of a radiolabeled targeted marker of angiogenesis in rat model of myocardial hypertrophy and ischemic injury[J]. J Physiol Pharmacol,2009,60(Suppl 4) : 117-123.

二级参考文献35

  • 1Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
  • 2Hicklin DJ, Ellis LM. Role of the vascular endothe- lial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027.
  • 3Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti- EGFR agents. Mol Cancer Res 2007; 5:203-220.
  • 4Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 2006; 64:33-37.
  • 5Banks RE, Forbes MA, Kinsey SE, Stanley A, Ing- ham E, Walters C, Selby PJ. Release of the angio- genic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF mea- surements and cancer biology. Br J Cancer 1998; 77: 956-964.
  • 6Smith GP. Filamentous fusion phage: novel expres- sion vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-1317.
  • 7Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249:386-390.
  • 8Yao X, Hu JF, Daniels M, Yien H, Lu H, Sharan H, Zhou X, Zeng Z, Li T, Yang Y, Hoffman AR. A nov- el orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res 2003; 9:2719-2726.
  • 9Zhong G, Zhang S, Li Y, Liu X, Gao R, Miao Q, Zhen Y. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xeno- graft in athymic mice. Cancer Lett 2010; 295:124-133.
  • 10Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003; 52:281-296.

共引文献1

江苏医药
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部